Year: 2024

Phase 2 Study Initiated to Evaluate Jaguar Health’s Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies -...

2025 Mobile EHR Global Report: Advancing Cloud-Based Digital Health Records in Europe. Africa and the Middle East – Black Book Research

Black Book unveils its 2025 global survey on mobile electronic health records, showcasing how non-U.S. nations are leveraging innovative platforms...

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies...

Interactive Strength Inc. (Nasdaq:TRNR) Secures 162 Unit CLMBR Commitment and Signs Exclusive Distribution Agreement With Planet Fitness SAS for France

Three-Year Agreement Expected to Generate more than $0.5million in Revenue, and Covers France and French RegionsFrance is the Second-Largest Fitness...

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to...

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The...

error: Content is protected !!